Digoxin Use in CAPD Patients

Introduction to Digoxin Therapy

The American Heart Association recommends lower initial doses of digoxin in CAPD patients, starting with 0.125 mg daily or every other day 1, 2
The European Society of Cardiology suggests that loading doses are generally not required in stable patients 3
Maintenance dosing should be individualized based on patient's age, with lower doses if over 70 years old 4

The American College of Cardiology recommends maintenance dosing based on body mass, with lower doses if low lean body mass 1, 2
Regular monitoring of serum digoxin levels is mandatory in CAPD patients, with target serum concentration in the range of 0.5-0.9 ng/mL 1, 2, 5
Levels above 2 ng/mL are commonly associated with overt toxicity, but toxicity may occur at lower levels in patients with renal impairment 1, 6

Major adverse effects of digoxin include cardiac arrhythmias, gastrointestinal symptoms, and neurological complaints 1, 2
Risk factors for digoxin toxicity in CAPD patients include electrolyte disturbances, hypothyroidism, and drug interactions 1, 6

Digoxin may be considered in CAPD patients with symptomatic heart failure with reduced ejection fraction (HFrEF) despite guideline-directed medical therapy 4
For heart failure management, digoxin has been downgraded from Class I to Class IIa/IIb recommendation in heart failure guidelines 4, 7
Digoxin may reduce hospitalizations but has no mortality benefit 1
For atrial fibrillation, digoxin is useful for initial control of ventricular rate 3
Beta-blockers are usually more effective when added to digoxin for rate control, particularly during exercise 1

The American Heart Association recommends monitoring heart rate and rhythm regularly in patients taking digoxin, as it can cause bradycardia, heart blocks, and various arrhythmias 8
Assessing for signs of toxicity, including nausea, vomiting, abdominal discomfort, visual disturbances, altered mental status, weakness, and cardiac arrhythmias, is crucial in patients taking digoxin 9

Elderly patients are at higher risk for digoxin toxicity due to age-related changes in pharmacokinetics and reduced renal function, and require more frequent monitoring of renal function and digoxin levels 9
The American College of Cardiology suggests monitoring for signs of worsening heart failure when digoxin therapy is initiated or doses are changed in heart failure patients 9

In cases of suspected toxicity, the American Heart Association recommends immediately withholding further doses and notifying the provider 8
For severe toxicity with life-threatening arrhythmias, heart block, or significant hyperkalemia, digoxin-specific antibody fragments (digoxin-Fab) are the treatment of choice, according to the American Heart Association 8